1.陕西中医药大学第一临床医学院,咸阳 712046
2.北京中医药大学教育部中医养生学重点实验室, 北京 100029
3.北京中医药大学科技处,北京 100029
钟欣妤,女,28岁,硕士,住院医师。研究方向:中医药防治老年病、内分泌及代谢性疾病的临床及基础研究。
刘铜华,E-mail:thliu@vip.163.com
收稿:2025-12-27,
纸质出版:2026-03-25
移动端阅览
钟欣妤,王宁,苏通,等.不忘散治疗阿尔茨海默病的作用及机制研究[J].北京中医药,2026,45(3):349-357.
ZHONG Xinyu,WANG Ning,SU Tong,et al.Efficacy and mechanisms of Buwang Powder in treating Alzheimer's disease[J]. Beijing Journal of Traditional Chinese Medicine,2026,45(03):349-357.
钟欣妤,王宁,苏通,等.不忘散治疗阿尔茨海默病的作用及机制研究[J].北京中医药,2026,45(3):349-357. DOI: 10.16025/j.1674-1307.2026.03.012.
ZHONG Xinyu,WANG Ning,SU Tong,et al.Efficacy and mechanisms of Buwang Powder in treating Alzheimer's disease[J]. Beijing Journal of Traditional Chinese Medicine,2026,45(03):349-357. DOI: 10.16025/j.1674-1307.2026.03.012.
目的
2
通过网络药理学及动物实验研究,探讨中药复方不忘散对阿尔茨海默病(AD)的潜在作用靶点。
方法
2
用网络药理学预测不忘散和AD的相关靶点。将24只雄性6月龄淀粉样前体蛋白/早老蛋白1(APP/PS1)小鼠编号后通过SPSS25.0软件随机数字表法分为模型组、多奈哌齐组、不忘散组各8只,8只雄性同月龄C57/BL6J小鼠作为正常组。正常组、模型组予纯水(1 mL/100 g体质量)灌胃,多奈哌齐组予多奈哌齐(0.065 mg/mL,1 mL/100 g体质量)灌胃,不忘散组予不忘散(0.936 g/mL,1 mL/100 g体质量)灌胃,每天1次,持续给药1个月。采用新物体识别实验和Morris水迷宫实验检测各组小鼠学习和空间记忆与探索能力,苏木精-伊红(HE)染色观察各组小鼠海马神经元的数量和形态,Western blotting实验检测小鼠海马中磷脂酰肌醇3-激酶(PI3K)/蛋白激酶B(AKT)、磷酸化蛋白激酶B(p-AKT)、糖原合成酶激酶3β(GSK3β)、磷酸化GSK3β(p-GSK3β)、APP表达。
结果
2
从不忘散中筛选出多个有效成分,其中AKT1的Degree值为57、PIK3R1的Degree值为31、GSK3β的Degree值为26;与不忘散治疗AD相关的信号通路有低氧诱导因子-1信号通路(HIF-1)信号通路、环磷酸腺苷信号通路(cAMP)信号通路、PI3K/AKT信号通路等;分子对接分析表明AKT1与不忘散中主要成分结合能力较强。动物实验表明:与模型组比较,不忘散组小鼠新物体识别实验中辨别指数高(
P
<
0.05)、Morris水迷宫实验逃避潜伏期短(
P
<
0.05)以及穿越平台次数多(
P
<
0.05);HE染色发现,不忘散组的海马区域细胞较模型组细胞致密,排列整齐,核仁清晰,细胞质染色均匀。不忘散组海马中PI3K表达及p-AKT/AKT、p-GSK3β/GSK3β高(P
<
0.05),APP表达低(
P
<
0.05)。
结论
2
不忘散可能通过调控PI3K/AKT/GSK3β信号通路,上调p-AKT、PI3K及p-GSK3β蛋白表达,下调APP表达,减少Aβ沉积,从而改善APP/PS1小鼠的学习记忆能力。
Objective
2
To investigate the potential targets of the Chinese medicine compound formula
Buwang Powder
in Alzheimer's disease(AD)through network pharmacology and animal experiments.
Methods
2
Network pharmacology was used to predict potential targets of
Buwang Powder
and AD.Twenty-four male 6-month-old amyloid precursor p
rotein/presenilin 1(APP/PS1)mice were numbered and randomly divided into a model group,a donepezil group, and a
Buwang Powder
group(8 mice per group)using SPSS 25.0 software with a random number table. Eight age-matched male C57BL/6J mice were used as the normal group.The normal and model groups received distilled water(1 mL/100 g body weight) by gavage, the donepezil group received donepezil solution (0.065 mg/mL,1 mL/100 g body weight),and the
Buwang Powder
group received
Buwang Powder
solution (0.936 g/mL,1 mL/100 g body weight),once daily for 1 month.The novel object recognition test and Morris water maze were used to assess learning,spatial memory,and exploratory ability.Hematoxylin-eosin(HE)staining was used to observe the number and morphology of hippocampal neurons.Western blot analysis was performed to detect the expression of phosphatidylinositol 3-kinase(PI3K),protein kinase B(AKT),phosphorylated AKT(p-AKT),glycogen synthase kinase 3β(GSK3β),phosphorylated GSK3β(p-GSK3β),and APP in the hippocampus.
Results
2
Network pharmacology identified multiple active components in
Buwang Powder
, with AKT1(degree=57),PIK3R1(degree=31),and GSK3β(degree=26)as key targets.The signaling pathways associated with
Buwang Powder
in the treatment of AD included the hypoxia-inducible factor-1(HIF-1)pathway,cyclic adenosine monophosphate(cAMP)pathway, and PI3K/AKT signaling pathway. Molecular docking analysis showed strong binding affinity between AKT1 and the main active components of
Buwang Powder
.Animal experiments showed that,compared with the model group,the
Buwang Powder
group had a significantly higher discrimination index in the novel object recognition test(
P
<
0.05),shorter escape latency in the Morris water maze(
P
<
0.05),and a greater number of platform crossings(
P
<
0.05).HE staining revealed that hippocampal neuro
ns in the
Buwang Powder
group were more densely arranged,more orderly,with clearer nucleoli and more uniform cytoplasmic staining compared with the model group.Western blot results showed that PI3K expression and the ratios of p-AKT/AKT and p-GSK3β/GSK3β were significantly increased in the
Buwang Powder
group(
P
<
0.05),while APP expression was significantly decreased(
P
<
0.05).
Conclusion
2
Buwang Powder
may improve learning and memory in APP/PS1 mice by regulating the PI3K/AKT/GSK3β signaling pathway,upregulating PI3K,p-AKT,and p-GSK3β expression,downregulating APP expression,and thereby reducing Aβ deposition.
SCHELTENS P , DE STROOPER B , KIVIPELTO M , et al . Alzheimer's disease [J ] . TLancet , 2021 , 397 ( 10284 ): 1577 - 1590 .
ZHANG H , WEI W , ZHAO M , et al . Interaction between Aβ and Tau in the Pathogenesis of Alzheimer's Disease [J ] . Int J Biol Sci , 2021 , 17 ( 9 ): 2181 - 2192 .
Abdulkhaliq AA , Kim B , Almoghrabi YM , et al . Amyloid-β and Tau in Alzheimer’s disease: pathogenesis, mechanisms, and interplay [J ] . Cell Death & Disease , 2026 , 17 ( 1 ): 21 .
VRANCX C , ANNAERT W . Amyloid precursor protein carboxy-terminal fragments as catalyzers of endolysosomal dysfunction in Alzheimer's disease [J ] . Trends Neurosci , 2025 , 48 ( 7 ): 538 - 551 .
郭雨菲 , 王成祥 , 孙慧媛 , 等 . 荆银双解散基于PI3K/AKT信号通路治疗甲型流感病毒感染小鼠的作用机制研究 [J ] . 北京中医药 , 2025 , 44 ( 1 ): 68 - 75 .
FENG Q , YU X , XIE J , et al . Phillygenin improves diabetic nephropathy by inhibiting inflammation and apoptosis via regulating TLR4/MyD88/NF-κB and PI3K/AKT/GSK3β signaling pathways [J ] . Phytomedicine , 2025 , 136 : 156314 .
ALQAHTANI SM , AL-KURAISHY HM , AL-GAREEB AI , et al . Pharmacological modulation of the PI3K/AKT/GSK3β axis: a new frontier in Alzheimer’s disease treatment [J ] . Inflammopharmacology , 2026 , 34 ( 1 ): 267 - 283 .
YOON JH , LEE N , YOUN K , et al . Dieckol ameliorates Aβ production via PI3K/AKT/GSK-3β regulated APP processing in SweAPP N2a cell [J ] . Mar Drugs , 2021 , 19 ( 3 ): 152 .
咸培伟 , 高丽美 , 杨煜珂 . 电针对阿尔茨海默病模型小鼠的治疗作用及机制 [J ] . 北京中医药 , 2022 , 41 ( 2 ): 136 - 140 .
赵凡莹 , 张红晓 , 李纳川 , 等 . 天麻素通过Nrf2/GPX4信号通路调控铁死亡对高血压合并血管性痴呆大鼠神经损伤的治疗作用观察 [J ] . 北京中医药 , 2024 , 43 ( 12 ): 1378 - 1384 .
田金洲 , 时晶 . 阿尔茨海默病的中医诊疗共识 [J ] . 中国西医结合杂志 , 2018 , 38 ( 5 ): 523 - 529 .
0
浏览量
1
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备 11010102006710号